ANTONY, GRENOBLE France, December 13 /PRNewswire-FirstCall/ -- STALLERGENES S.A and Protein'eXpert S.A. announce they have signed a partnership agreement for developing and pharmaceutically producing mites recombinant allergens(1).
The partnership is part of the STALLERGENES "Enhanced Allergens" innovation programme for a recombinant protein treatment for sublingual desensitisation of allergy to mites. This second-generation treatment is made up of the recombinant allergens Der p 1 and Der p 2 in the form of a fusion protein, combined with an adjuvant and/or a mucoadhesive formulation for facilitating recognition of the allergen by the immune system.
Protein'eXpert will handle:
- developing processes aimed at optimising the existing production protocol;
- developing and scaling up fermentation, renaturation, and purification processes;
- producing preclinical and clinical batches.
"This partnership enables us to accelerate the development of our "Enhanced Allergens" programme, and to envisage moving rapidly on to humans in a phase I study," emphasizes Philippe Moingeon, Scientific Director of STALLERGENES. Protein'eXpert has indeed recognised know-how in the field of process development and cGMP(2) biomanufacturing."
"Protein'eXpert is very pleased to be taking part in an innovative development programme in the specific field of respiratory allergy immunotherapy," declares Nicolas Mouz, Chief Scientific Director at Protein'eXpert. "'This partnership offers us an opportunity to propose our expertise in protein engineering and therapeutic protein development, and to widen our knowledge of allergens."
About the "Enhanced Allergens" programme
The combination of molecular biology tools and of
formulation/adjuvanting strategies makes it possible to target better the
immune system of the sublingual mucous membrane, and to improve the
efficacy of desensitisation treatments. It is on this major concept tha
Copyright©2007 PR Newswire.
All rights reserved